Document is current
Any future updates will be listed below
-
Authors
Ivanchenko, Maryna V. https://orcid.org/0000-0003-0754-1427
Booth, Kevin T. A.
Karavitaki, K. Domenica
Antonellis, Larisa M.
Nagy, M. Aurel https://orcid.org/0000-0003-4608-1152
Peters, Cole W.
Price, Spencer
Li, Yaqiao
Lytvyn, Anton
Ward, Andrew
Griffith, Eric C. https://orcid.org/0000-0003-0428-3215
Hrvatin, Sinisa https://orcid.org/0000-0001-7303-4218
Greenberg, Michael E. https://orcid.org/0000-0003-1380-2160
Corey, David P. https://orcid.org/0000-0003-4497-6016
- License Information
-
More Information
Article History
Received: 22 April 2025
Accepted: 30 October 2025
First Online: 16 December 2025
Competing interests
: M.V.I. is a consultant to and holds equity in Skylark Bio. K.D.K. is an employee and holds equity in Skylark Bio. D.P.C. holds equity in Skylark Bio. These relationships are unrelated to the specific research presented in this manuscript. M.V.I., K.T.B., S.H., M.A.N., C.W.P., E.C.G., M.E.G., and D.P.C. are inventors on patent application US20230340038A1, Recombinant adeno associated virus (raav) encoding gjb2 and uses thereof . All other authors declare no competing interests.
